Literature DB >> 8296617

Autoantibodies directed against lysozyme: a new target antigen for anti-neutrophil cytoplasmic antibodies (ANCA).

W H Schmitt1, E Csernok, B K Flesch, S Hauschild, W L Gross.   

Abstract

ANCA-positive sera from 1138 patients and ANCA-negative sera from 90 patients were screened for autoantibodies directed against lysozyme (LZ) by ELISA. Sera from 120 patients did react with LZ. 99 sera bound to LZ only, whereas 56 sera bound to further granule proteins, especially cathepsin G and lactoferrin. In the routine ANCA screening, most of the anti-LZ-positive sera showed a pANCA fluorescence. In total, 8% of 674 pANCA-positive sera did react with LZ. Clinically, anti-LZ antibodies were associated inflammatory rheumatologic, -renal and -bowel diseases.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8296617     DOI： 10.1007/978-1-4757-9182-2_40

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


  11 in total

Review 1.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 2.  The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens.

Authors:  A Wiik; L Stummann; L Kjeldsen; N Borregaard; S Ullman; S Jacobsen; P Halberg
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

Review 3.  ANCA testing. New developments and clinical implications.

Authors:  A E Ahmed; J B Peter; Y Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease.

Authors:  Jan G M C Damoiseaux; Bas Bouten; Annick M L W Linders; Jos Austen; Caroline Roozendaal; Maurice G V M Russel; Pierre-Philippe Forget; Jan Willem Cohen Tervaert
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

5.  Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel disease (IBD).

Authors:  C Roozendaal; M H Zhao; G Horst; C M Lockwood; J H Kleibeuker; P C Limburg; G F Nelis; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1998-04       Impact factor: 4.330

6.  Antineutrophil cytoplasmic antibodies (ANCA) in rheumatoid arthritis: a prospective study.

Authors:  E Röther; T Schochat; H H Peter
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

7.  Characterisation of autoantibodies to neutrophil granule constituents among patients with reactive arthritis, rheumatoid arthritis, and ulcerative colitis.

Authors:  H Locht; T Skogh; A Wiik
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

8.  Anti-neutrophil cytoplasm antibodies (ANCA) in rheumatoid arthritis: relationship to HLA-DR phenotypes, rheumatoid factor, anti-nuclear antibodies and disease severity.

Authors:  E Röther; D Metzger; B Lang; I Melchers; H H Peter
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

9.  Specificities of anti-neutrophil autoantibodies in patients with rheumatoid arthritis (RA).

Authors:  J Brimnes; P Halberg; S Jacobsen; A Wiik; N H Heegaard
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 10.  Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them?

Authors:  C Beauvillain; Y Delneste; G Renier; P Jeannin; J F Subra; A Chevailler
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.